- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01491256
Index of Microcirculatory Resistance After Drug-Eluting Stent Implantation With High Dose Atorvastatin Loading (RESIST-ACS)
December 11, 2011 updated by: Bong-Ki Lee, The Korean Society of Circulation
Randomized Comparison Multicenter Trial of High Dose Atorvastatin Pre-treatment on Microcirculatory Dysfunction After Drug-ElutIng Stent Implantation in Patients With Acute Coronary Syndrome
Pre-treatment with statins decreased the incidence of cardiac enzyme increase after percutaneous coronary intervention (PCI) and distal embolization suspected to cause post-PCI myocardial damage.
This study evaluates the effect of high dose atorvastatin pre-treatment on post-procedural index of microcirculatory resistance (IMR) values that are introduced for assessing the status of the microcirculation.
Study Overview
Status
Unknown
Conditions
Detailed Description
One hundred patients with non-ST elevation acute coronary syndrome will be randomly assigned to either high dose atorvastatin pre-treatment group(80 mg loading within 24 hours plus 40mg busting within 2 hours before PCI) or control group(atorvastatin 10mg administration within 24 hours before PCI).
An intracoronary pressure/temperature sensor-tipped guidewire is used.
Thermodilution curves are obtained during maximal hyperemia.
The IMR was calculated from the ratio of the mean distal coronary pressure at maximal hyperemia to the inverse of mean hyperemic transit time.
Creatine kinase-myocardial band(CK-MB) and CRP level will be measured at baseline and at 12~24 hours after PCI.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bong-Ki Lee, MD, PhD
- Phone Number: +82-10-6373-9290
- Email: nicedr@nate.com
Study Locations
-
-
-
Chuncheon, Korea, Republic of, 200-722
- Recruiting
- Kangwon National University Hospital
-
Principal Investigator:
- Chang-Wook Nam, MD, PhD
-
Principal Investigator:
- Seung-Woon Rha, MD, PhD
-
Contact:
- Bong-Ki Lee, MD, PhD
- Phone Number: +82-10-6373-9290
- Email: nicedr@nate.com
-
Principal Investigator:
- Joon-Hyung Doh, MD, PhD
-
Principal Investigator:
- Woo-Young Chung, MD, PhD
-
Principal Investigator:
- Seung-Jae Tahk, MD, PhD
-
Principal Investigator:
- Jin-Bae Lee, MD, PhD
-
Principal Investigator:
- Ki-Dong Yoo, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients of Non-ST elevation acute coronary syndrome planed to elective percutaneous coronary intervention
Exclusion Criteria:
- ST elevation myocardial infarction
- Cardiogenic shock
- Congestive heart failure with pulmonary edema
- Severe left ventricular dysfunction (LVEF < 30%)
- History of previous coronary revascularization therapy
- chronic total coronary occlusion
- 3 vessel disease
- Target lesion at distal segments or branches
- Ostial lesion
- Excessive coronary calcification or thrombi
- Elevated transaminase
- Renal dysfunction (serum creatinine > 2.0mg/dL
- History of myopathy
- Contra-indication to anti-platelet therapy
- Not indicated for percutaneous coronary intervention
- Other co-morbidity with life expectancy less than 1 year
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: High dose Atorvastatin
Arm of pre-procedural high dose atorvastatin loading
|
Atorvastatin 80 mg loading within 24 hours plus 40mg busting within 2 hours before percutaneous coronary intervention
Other Names:
|
Placebo Comparator: Control
No pre-procedural high dose atorvastatin loading
|
atorvastatin 10mg administration within 24 hours before percutaneous coronary intervention
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Index of microcirculatory resistance (IMR)
Time Frame: Immediately after percutaneous coronary intervention
|
After stent implantation and adjunctive balloon dilatation, final angiogram will be taken.
If the final angiogram shows successful results, IMR will be measured and the procedure will be finished.
|
Immediately after percutaneous coronary intervention
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Major Adverse Cardiovascular Events (death, myocardial infarction, target vessel failure
Time Frame: 1 year after index procedure
|
1 year after index procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (Actual)
November 1, 2011
Study Completion (Anticipated)
February 1, 2012
Study Registration Dates
First Submitted
December 1, 2011
First Submitted That Met QC Criteria
December 11, 2011
First Posted (Estimate)
December 13, 2011
Study Record Updates
Last Update Posted (Estimate)
December 13, 2011
Last Update Submitted That Met QC Criteria
December 11, 2011
Last Verified
December 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Disease
- Syndrome
- Acute Coronary Syndrome
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Atorvastatin
Other Study ID Numbers
- RESIST-ACS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Yonsei UniversityCompletedAcute Coronary Syndrome (ACS)Korea, Republic of
Clinical Trials on Pre-procedural High dose atorvastatin loading
-
Central South UniversityUnknownStable Angina | Unstable Angina | Acute Non-ST-segment Elevation Myocardial InfarctionChina
-
Hippocration General HospitalCompletedCoronary Artery Disease | Atherosclerosis | Endothelial Dysfunction | Oxidative Stress | HMG-CoA Reductase Inhibitor ToxicityGreece
-
Beijing HospitalUnknownCarotid Artery StenosisChina
-
Hormozgan University of Medical SciencesCompletedCardiovascular DiseaseIran, Islamic Republic of
-
Wakayama Medical UniversityCompletedAtherosclerosis | Dyslipidemia | Acute Coronary SyndromeJapan
-
Yuejin YangPeking Union Medical College Hospital; The First Hospital of Hebei Medical... and other collaboratorsUnknownMyocardial Infarction | Stem Cell Transplantation | Angioplasty, Transluminal, Percutaneous Coronary
-
Centre Hospitalier Universitaire de NīmesCentre Hospitalier Lyon Sud; Hôpital Haut-LévêqueUnknown
-
Yonsei UniversityUnknownDrug-eluting Stent (DES)Korea, Republic of
-
Daniel BenjaminPediatric Pharmacology Research Units NetworkCompletedCandidiasisUnited States
-
Samsung Medical CenterDon-A Pharmaceutical, Seoul, South KoreaUnknownStroke | Intracranial AtherosclerosisKorea, Republic of